Techniques in Regional Anesthesia & Pain Management
Volume 9, Issue 4 , Pages 216-220 , October 2005

Buprenorphine for pain management physicians: A dilemma or a therapeutic alternative?

  • David P. Myers, MD (FASAM)

      Affiliations

    • The Opiate Maintenance Program, HealthCare Connection of Tampa, Inc., Tampa, Florida
    • ,
  • Michael Augustyniak, MD

      Affiliations

    • Addiction Medicine Section, Department of Anesthesia, University of South Florida, Tampa, Florida
    • ,
  • Joseph Molea, MD (FASAM)

      Affiliations

    • The Opiate Maintenance Program, HealthCare Connection of Tampa, Inc., Tampa, Florida
    • Addiction Medicine Section, Department of Anesthesia, University of South Florida, Tampa, Florida
    • Corresponding Author InformationAddress reprint requests and correspondence: Joseph Molea, MD, USF Dept. of Anesthesia, Cypress Medical Group, 5820 Cypress Street, Suite B, Tampa, Florida 33607.

References 

  1. Raisch DW , Fye CL , Boardman KD , et al.   Opioid dependence treatment, including buprenorphine/naloxone . Ann Pharmacother . 2002;36:312–321
  2. Merrill JO . Policy progress for physician treatment of opiate addiction . J Gen Intern Med . 2002;17:361–368
  3. Mark TL , Woody GE , Juday T , et al.   The economic costs of heroin addiction in the United States . Drug Alcohol Depend . 2001;61:195–206
  4. Rounsaville BJ , Kosten TR . Treatment for opioid dependence (quality and access) . JAMA . 2000;283:1337–1339
  5. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction . Effective medical treatment of opiate addiction . JAMA . 1998;280:1936–1943
  6. Resnick RB . Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction . [letter] Ann Intern Med . 2003;138:360
  7. Fiellin DA , O’Connor PG . Clinical practice (office-based treatment of opioid-dependent patients) . N Engl J Med . 2002;347:817–823
  8. Jaffe JH , O’Keeffe C . From morphine clinics to buprenorphine (regulating opioid agonist treatment of addiction in the United States) . Drug Alcohol Depend . 2003;70:S3–S11
  9. Fiellin DA , O’Connor PG . New federal initiatives to enhance the medical treatment of opioid dependence . Ann Intern Med . 2002;137:688–692
  10. Buprenorphine training from SAMSHA [Substance Abuse and Mental Health Services Administration Web site]. Available at http://buprenorphine.samhsa.gov. Accessed October 30, 2003.
  11. Ling W , Smith D . Buprenorphine (blending practice and research) . J Subst Abuse Treat . 2002;23:87–92
  12. Pickworth WB , Johnson RE , Holicky BA , et al.   Subjective and physiologic effects of intravenous buprenorphine in humans . Clin Pharmacol Ther . 1993;53:570–576
  13. Mendelson J , Upton RA , Everhart ET , et al.   Bioavailability of sublingual buprenorphine . J Clin Pharmacol . 1997;37:31–37
  14. Ohtani M , Kotaki H , Nishitateno K , et al.   Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine . J Pharmacol Exp Ther . 1997;281:428–433
  15. Ohtani M , Kotaki H , Sawada Y , et al.   Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling . J Pharmacol Exp Ther . 1995;272:505–510
  16. Bridge TP , Fudala PJ , Herbert S , et al.   Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence . Drug Alcohol Depend . 2003;70:S79–S85
  17. Chiang CN , Hawks RL . Pharmacokinetics of the combination tablet of buprenorphine and naloxone . Drug Alcohol Depend . 2003;70:S39–S47
  18. Mendelson J , Jones RT , Fernandez I , et al.   Buprenorphine and naloxone interactions in opiate-dependent volunteers . Clin Pharmacol Ther . 1996;60:105–114
  19. Mendelson J , Jones RT , Welm S , et al.   Buprenorphine and naloxone combinations (the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers) . Psychopharmacology (Berl) . 1999;141:37–46
  20. Auriacombe M , Franques P , Tignol J . Deaths attributable to methadone vs buprenorphine in France . [letter] JAMA . 2001;285:45
  21. Lintzeris N , Bell J , Bammer G , et al.   A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal . Addiction . 2002;97:1395–1404
  22. Johnson RE , Eissenberg T , Stitzer ML , et al.   A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence . Drug Alcohol Depend . 1995;40:17–25
  23. Ling W , Charuvastra C , Collins JF , et al.   Buprenorphine maintenance treatment of opiate dependence (a multicenter, randomized clinical trial) . Addiction . 1998;93:475–486
  24. O’Connor PG , Oliveto AH , Shi JM , et al.   A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic . Am J Med . 1998;105:100–105
  25. Johnson RE , Chutuape MA , Strain EC , et al.   A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence . N Engl J Med . 2000;343:1290–1297
  26. Fudala PJ , Bridge TP , Herbert S , et al.   Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone . N Engl J Med . 2003;349:949–958
  27. The 2003 National Survey on Drug Use and Health, Department of Health and Human Services Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Available at: http://www.oas.samhsa.gov/nhsda/. Accessed September 27, 2005
  28. Compton P , Charuvastra VC , Ling W . Pain intolerance in opioid-maintained former opiate addicts (effect of long-acting maintenance agent) . Drug Alcohol Depend . 2001;63:139–146
  29. Harper I . Temgesic abuse . [letter] N Z Med J . 1983;96:777
  30. Rainey HB . Abuse of buprenorphine . [letter] N Z Med J . 1986;99:72
  31. Tacke U . Abuse of buprenorphine by intravenous injection (the French connection) . [letter] Addiction . 2002;97:1355
  32. Quigley AJ , Bredemeyer DE , Seow SS . A case of buprenorphine abuse . Med J Aust . 1984;140:425–426
  33. Obadia Y , Perrin V , Feroni I , et al.   Injecting misuse of buprenorphine among French drug users . Addiction . 2001;96:267–272
  34. Robinson GM , Dukes PD , Robinson BJ , et al.   The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand . Drug Alcohol Depend . 1993;33:81–86
  35. Tracqui A , Kintz P , Ludes B . Buprenorphine-related deaths among drug addicts in France (a report on 20 fatalities) . J Anal Toxicol . 1998;22:430–434
  36. Reynaud M , Petit G , Potard D , et al.   Six deaths linked to concomitant use of buprenorphine and benzodiazepines . Addiction . 1998;93:1385–1392
  37. Reynaud M , Tracqui A , Petit G , et al.   Six deaths linked to misuse of buprenorphine-benzodiazepine combinations . Am J Psychiatry . 1998;155:448–449
  38. Gaulier JM , Marquet P , Lacassie E , et al.   Fatal intoxication following self-administration of a massive dose of buprenorphine . J Forensic Sci . 2000;45:226–228
  39. Thorn SE , Rawal N , Wennhager M . Prolonged respiratory depression caused by sublingual buprenorphine . Lancet . 1988;1:179–180
  40. Downing JW , Goodwin NM , Hicks J . The respiratory depressive effects of intravenous buprenorphine in patients in an intensive care unit . S Afr Med J . 1979;55:1023–1027
  41. Schmidt JF , Chraemmer-Jorgensen B , Pedersen JE , et al.   Postoperative pain relief with naloxone (severe respiratory depression and pain after high dose buprenorphine) . Anaesthesia . 1985;40:583–586
  42. Boyd J , Randell T , Luurila H , et al.   Serious overdoses involving buprenorphine in Helsinki . Acta Anaesthesiol Scand . 2003;47:1031–1033
  43. Banks CD . Overdosage of buprenorphine (case report) . N Z Med J . 1979;89:255–257
  44. Gal TJ . Naloxone reversal of buprenorphine-induced respiratory depression . Clin Pharmacol Ther . 1989;45:66–71

PII: S1084-208X(05)00086-8

doi: 10.1053/j.trap.2005.10.007

Techniques in Regional Anesthesia & Pain Management
Volume 9, Issue 4 , Pages 216-220 , October 2005

Article Tools